WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 510242
Description: SB-202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. The inhibitory activity of SB 202190 on CREB phosphorylation was independent of p38, but instead correlated with inhibition of casein kinase 1 (CK1) in vitro.
MedKoo Cat#: 510242
Chemical Formula: C20H14FN3O
Exact Mass: 331.11209
Molecular Weight: 331.34
Elemental Analysis: C, 72.50; H, 4.26; F, 5.73; N, 12.68; O, 4.83
SB-202190, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: SB202190; SB202190; SB 202190.
IUPAC/Chemical Name: 4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol
InChi Key: QHKYPYXTTXKZST-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,25H,(H,23,24)
SMILES Code: OC1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1
The following data is based on the product molecular weight 331.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Glover M, Sweeny C, Davis B, O'Shaughnessy KM. A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190. Open Med Chem J. 2010 Sep 3;4:57-61. doi: 10.2174/1874104501004010057. PubMed PMID: 21249167; PubMed Central PMCID: PMC3023092.
2: Shanware NP, Williams LM, Bowler MJ, Tibbetts RS. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB Rep. 2009 Mar 31;42(3):142-7. PubMed PMID: 19336000.